Skip to content

Long Term Outcomes in COVID-19 Patients Recruited in the CORIST Project

Long Term Outcomes in COVID-19 Patients Recruited in the CORIST Project: Longitudinal Data and Case-control Study

Status
Withdrawn
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04907890
Acronym
CORIST-2
Enrollment
0
Registered
2021-06-01
Start date
2022-06-14
Completion date
2023-05-30
Last updated
2022-09-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Long Covid19, Sars-CoV-2 Infection

Keywords

Sars-CoV-2, Long Covid19, Case-control study

Brief summary

Months after seemingly recovering from COVID-19, many patients continue to suffer from major long-term effects. Interestingly, the existence of direct link between the severity of the disease in its acute phase and the severity of the long-lasting symptoms is uncertain. We aim at characterizing the long term outcomes in patients hospitalised for COVID-19 including symptoms, medical history, persistent organ damage and neurological and behavioural sequelae.

Detailed description

The aims of this project are: 1) to estimate the degree of physical disability, including psychological sequelae, in survivors of COVID-19 \>1-year post hospital discharge and how these long term effect are related to COVID-19 or Sars-Cov-2 infection; 2) to assess if a link between the severity or the treatment of the disease in its acute phase and the severity of the long-lasting symptoms exists. Aims will be accomplished by using data from the COVID-19 RISK and Treatments (CORIST) Project (ClinicalTrials.gov ID: NCT04318418). The CORIST study included N=4,396 patients hospitalized for SARS-Cov-2 infection in 35 hospitals across Italy, between February 2020 and May 2020. Within each participating hospital, clinical data were abstracted from electronic medical records. Collected data included patients' demographics, laboratory tests, medications in use, history of disease and prescribed pharmacological therapy for COVID-19 treatment. Information on the most severe manifestation of COVID-19 occurred during hospitalization was also captured. All survivor patients previously recruited in the CORIST study (N=3,648), will be reached by phone by the hospital in which they were healed for COVID-19, informed about the research objectives and procedure and, if they will accept to participate, they will ask to sign an institutional review board consent electronic form. Participants will be requested to return a series of web-based, validated questionnaires aimed at evaluating: 1) occurrence of COVID-19-related symptoms such as fatigue, dizziness, etc.; 2) behavioural features and modifications (e.g., disturbances in sleep, vision, hearing or olfaction); 3) neuropsychological evaluation, regarding multiple cognitive domains (e.g. memory domain, motivational factors, emotional state assessment, mood disturbance and quality of life); 4) change in dietary habits. Aim 1 Each participant (case) will be asked to select two control subjects with the following characteristics: control1) same sex, ±5 years, who had a positive diagnosis for SARS-Cov-2 infection in the past (at least 6±2 months) and that was never hospitalised for COVID-19 as he/she had not severe symptoms and control2) same sex, ±5 years, who was never diagnosed for SARS-Cov-2 infection. Each accepting control will be asked to return similar (appropriately modified) questionnaires as cases. Comparisons of cases with control1 individuals will offer evidence of long-term effects due to severity of COVID-19, whereas contrasts of cases or control1 with control2 persons will give indication of long-term effects due to SARS-Cov-2 infection, irrespective from COVID-19. Aim 2 We expect that a large proportion of case patients has undergone a medical visit in the months after recovering by COVID-19, in the same hospital in which they were healed. For these patients, all available medical information (data on fibrosis, dyspnoea, thoracic pain, respiratory, cardiac, neurological and psychiatric diseases) gathered at follow-up visit will be collected. This bulk of information, together with that attained from questionnaires as described in aim 1 will be related to data (already available to us) from CORIST project and will allow test if a link between the severity or the management in hospital of the disease in its acute phase and the severity of the long-lasting symptoms exists.

Interventions

None listed

Sponsors

Clinica Mediterranea
CollaboratorOTHER
Neuromed IRCCS
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

cases: survivor patients previously recruited in the CORIST study

Exclusion criteria

\-

Design outcomes

Primary

MeasureTime frameDescription
Medical symptoms1 yearOccurrence of COVID-19-related medical symptoms

Secondary

MeasureTime frameDescription
Difference between cases and controls in behavioural features as assessed by PHQ-9 Depression Test Questionnaire1 yearDifferences will be evaluated contrasting cases with both two types of controls and comparing the two groups of controls each other
Difference between cases and controls in physicological features as assessed by GAD7 Anxiety Test Questionnaire1 yearDifferences will be evaluated contrasting cases with both two types of controls and comparing the two groups of controls each other
Difference between cases and controls in physicological features as assessed by the Psychological resilience Test (CONNOR-DAVIDSON - 10 items)1 yearDifferences will be evaluated contrasting cases with both two types of controls and comparing the two groups of controls each other
Difference between cases and controls in dietary habits as assessed by the mediterranean diet adherence score1 yearDifferences will be evaluated contrasting cases with both two types of controls and comparing the two groups of controls each other

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026